Skip to content
CFPS Research Archives

Ribupatide

Human clinical Weight Loss & Metabolism 2 sources

Ribupatide (also known as HRS9531 or KAI-9531) is an investigational dual GLP-1 and GIP receptor agonist currently in Phase 3 clinical trials. Research demonstrates its potential to induce significant weight loss and improve metabolic markers in individuals with obesity and type 2 diabetes, with both once-weekly injectable and once-daily oral formulations under investigation.

01Dosing reference

Amount
Up to 10 mg (injectable) or varying oral doses in clinical trials
Frequency
Once weekly (injectable) or once daily (oral)
Cycle
Continuous use with dose titration (e.g., over 76 weeks in Phase 3 trials)
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

Dual Receptor Activation

Ribupatide binds to and activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

02

Metabolic Regulation

Activation of these receptors enhances glucose-dependent insulin secretion, slows gastric emptying, and signals satiety in the brain.

03

Weight Loss and Glycemic Control

This dual action leads to reduced food intake, improved blood sugar levels, and significant reductions in body weight.

03Human evidence

Significant weight loss in Phase 2 trials

A Phase 2 clinical trial of once-daily oral ribupatide demonstrated weight loss of up to 12.1% in adults with obesity.

Efficacy in Phase 3 trials

Once-weekly subcutaneous injections of ribupatide are being evaluated in global Phase 3 trials (such as the KAINETIC program) for obesity and weight management.

04Preclinical evidence

Receptor binding affinity

In vitro studies demonstrated that ribupatide effectively binds to both GLP-1 and GIP receptors, showing potent dual agonism.

Metabolic improvements in animal models

Preclinical animal models of obesity and diabetes showed reduced food intake and improved glycemic control following ribupatide administration.

05What is known vs. unknown

Reasonably established
  • Ribupatide is a synthetic peptide acting as a dual GLP-1/GIP receptor agonist.
  • It is being developed in both once-weekly subcutaneous injection and once-daily oral formulations.
  • Clinical trials have shown it can achieve significant weight loss, with some studies reporting over 12% reduction in body weight.
  • It is currently advancing through Phase 3 clinical trials for the treatment of obesity and type 2 diabetes.
Unknowns & limits
  • Long-term safety and cardiovascular outcomes of ribupatide are still being evaluated in ongoing Phase 3 trials.
  • The exact differences in efficacy and tolerability between its oral and injectable formulations require further large-scale comparison.
  • It is not yet FDA-approved and remains an investigational drug.

06Safety & regulatory context

Regulatory statusRibupatide is currently an investigational drug and is not yet approved by the FDA or other regulatory agencies. As a GLP-1/GIP receptor agonist, its safety profile in clinical trials appears similar to other drugs in this class, with the most common side effects being gastrointestinal issues such as nausea, vomiting, diarrhea, and decreased appetite. It is being evaluated in rigorous Phase 3 clinical trials to fully establish its long-term safety, efficacy, and potential contraindications.

07Compared with Tirzepatide

Ribupatide vs. Tirzepatide
Key difference
Both are dual GLP-1/GIP receptor agonists, but ribupatide is being developed simultaneously as both a once-weekly injection and a once-daily oral medication, whereas tirzepatide is currently approved as a once-weekly injection.
When researchers discuss each
Researchers discuss tirzepatide as the first-in-class approved dual agonist for diabetes and weight loss, while ribupatide is discussed as an emerging next-generation candidate with promising oral bioavailability.

08Glossary

GLP-1 Receptor Agonist
A class of medications that mimic the GLP-1 hormone to stimulate insulin release, lower blood sugar, and reduce appetite.
GIP
Glucose-dependent insulinotropic polypeptide, a hormone that stimulates insulin secretion and plays a role in lipid metabolism.
Dual Agonist
A molecule that binds to and activates two different types of receptors simultaneously.

09Knowledge check

Q1What is the primary mechanism of action of ribupatide?
Q2Which formulations of ribupatide are currently being evaluated in clinical trials?
Q3Which documented limitation of the current ribupatide evidence is explicitly stated in the dossier?
Q4When researchers discuss how ribupatide compares with tirzepatide, what key difference does the dossier highlight?
Q5Which statement about ribupatide's regulatory or safety context is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism
Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism
Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism
Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.